SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer

Journal of Surgical Oncology

Volumn 112, Issue 2, 2015, Pages 231-237

  Azuma, Yoko ^a   Yokobori, Takehiko ^a   Mogi, Akira ^a   Altan, Bolag ^a   Yajima, Toshiki ^a   Kosaka, Takayuki ^a   Onozato, Ryoichi ^a   Yamaki, Ei ^a   Asao, Takayuki ^b   Nishiyama, Masahiko ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

autophagy; chemoresistance; sirtuin; sirtuin 6

Indexed keywords

BECLIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; SIRTUIN 6; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; SIRT6 PROTEIN, HUMAN; SIRTUIN; TUMOR MARKER;

A549 CELL LINE; ADULT; AGED; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; RNA INTERFERENCE; SINGLE BLIND PROCEDURE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SIRTUINS;

EID: 84940052405     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23975     Document Type: Article

References (20)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (Oxford, England: 1990) 2010; 46: 765-781.
2. Cufer T, Ovcaricek T, O'Brien ME,: Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years. Eur J Cancer (Oxford, England: 1990) 2013; 49: 1216-1225.
3. Jia G, Su L, Singhal S, et al.,: Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging. Mol Cell Biochem 2012; 364: 345-350.
4. Houtkooper RH, Pirinen E, Auwerx J,: Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13: 225-238.
5. Yuan H, Su L, Chen WY,: The emerging and diverse roles of sirtuins in cancer: A clinical perspective. Onco Targets Ther 2013; 6: 1399-1416.
6. Takasaka N, Araya J, Hara H, et al.,: Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence. J Immunol 2014; 192: 958-968.
7. White E,: Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12: 401-410.
8. Sebastian C, Zwaans BM, Silberman DM, et al.,: The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012; 151: 1185-1199.
9. Marquardt JU, Fischer K, Baus K, et al.,: Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology (Baltimore, Md) 2013; 58: 1054-1064.
10. Lai CC, Lin PM, Lin SF, et al.,: Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol 2013; 34: 1847-1854.
11. Liu Y, Xie QR, Wang B, et al.,: Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. Protein Cell 2013 Aug 27. [Epub ahead of print].
12. Khongkow M, Olmos Y, Gong C, et al.,: SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis 2013; 34: 1476-1486.
13. Zhong L, Mostoslavsky R,: SIRT6: A master epigenetic gatekeeper of glucose metabolism. Transcription 2010; 1: 17-21.
14. Lappas M,: Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells. Mediators Inflamm 2012; 2012: 597514.
15. Ardestani PM, Liang F,: Sub-cellular localization, expression and functions of Sirt6 during the cell cycle in HeLa cells. Nucleus (Austin, Tex) 2012; 3: 442-451.
16. Broet P, Dalmasso C, Tan EH, et al.,: Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res 2011; 17: 3542-3550.
17. Kang JU, Koo SH, Kwon KC, et al.,: Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 2009; 9: 237.
18. Zhan Z, Xie X, Cao H, et al.,: Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy 2014; 10: 257-268.
19. Soifer HS, Rossi JJ, Saetrom P,: MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007; 15: 2070-2079.
20. Pecot CV, Calin GA, Coleman RL, et al.,: RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer 2011; 11: 59-67.